Safety and immunogenicity of Ad26.COV2.S in adults: A randomised, double-blind, placebo-controlled Phase 2a dose-finding study
Author:
Cárdenas Vicky,
Le Gars Mathieu,
Truyers Carla,
Ruiz-Guiñazú JavierORCID,
Struyf Frank,
Colfer AliciaORCID,
Bonten Marc,
Borobia Alberto,
Reisinger Emil C.,
Kamerling Ingrid M.C.,
Douoguih Macaya,
Sadoff Jerald
Reference14 articles.
1. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study;Watson;Lancet Infect Dis,2022
2. Our World in Data. Coronavirus (COVID-19) Vaccinations. Accessed April 12, 2024. Available from https://ourworldindata.org/covid-vaccinations.
3. Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses;Bos;npj Vaccines,2020
4. Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial;Hardt;Lancet Infect Dis,2022
5. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19;Sadoff;N Engl J Med,2021